Sigma passed the worst of its woes The Australian Rival Australian Pharmaceutical Industries (API, 31c) reports on April 20 but has already flagged a poor result because of Queensland flood disruptions, the Pfizer factor, depressed consumer spending and non-prescription pharma competition from ... and more » |